Key statistics
On Friday, Vera Therapeutics Inc (VERA:NMQ) closed at 42.78, -15.75% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.05 |
---|---|
High | 43.02 |
Low | 41.51 |
Bid | 17.21 |
Offer | 45.36 |
Previous close | 41.99 |
Average volume | 658.36k |
---|---|
Shares outstanding | 54.83m |
Free float | 50.51m |
P/E (TTM) | -- |
Market cap | 2.35bn USD |
EPS (TTM) | -2.20 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
- Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics to Participate at September Investor Conferences
- Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
- Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
- Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
- Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
- Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
More ▼